New to Primatene® MIST

 

 

Primatene® MIST, the epinephrine inhaler propelled by chlorofluorocarbons (CFCs), was phased out in 2011 because the inhaler used CFCs as a propellant to move the medicine out of the inhaler so patients could breathe the medicine into their lungs. The United States signed an international agreement, called the Montreal Protocol on Substances that Deplete the Ozone Layer along with many other countries. In order to comply with obligations made under the Montreal Protocol on Substances that Deplete the Ozone Layer, participating countries agreed to phase-out substances that deplete the ozone layer, including CFCs.

 

 

The new Primatene® MIST is a CFC-free metered dose inhaler (MDI) that uses epinephrine as its active ingredient, the same active ingredient used in the previous Primatene® MIST. The new Primatene® MIST MDI propelled by hydrofluoroalkane (HFA 134a) works differently from the old Primatene® MIST inhaler containing CFCs. Be sure to read the Consumer Information Insert for detailed directions on how to correctly use your new Primatene® MIST metered dose inhaler.

 

 

The new medication container is a pressurized metal canister similar to canisters used in other metered dose inhalers available, instead of the glass container used in the previous Primatene® MIST inhaler propelled by chlorofluorocarbons (CFCs).

 

 

The new Primatene® MIST has a built in spray indicator that shows how many sprays of medication you have left in the container. A full container has 160 sprays. After every 20 sprays, the spray indicator number changes.

 

 

The new Primatene® MIST requires the user to perform the following steps the first time the inhaler is taken out of the box:

 

a. Remove red cap.

 

b. Hold inhaler with opening away from your face and others.

 

c. “Shake then test spray into the air”.

 

You must repeat both actions 4 times to activate your

new inhaler.

 

 

Every time you use your inhaler, before you take an inhalation, you must shake then spray into the air 1 time before each use.

 

Wash your inhaler after each day of use.

 

 

The maximum daily dose of Primatene® MIST is 8 inhalations in 24 hours.

You should see your doctor if you have more than 2 asthma attacks in a week.

 

 

Children under 12 years of age should not use Primatene® MIST.

It is not known if the drug works or is safe in children under age 12.

Adult supervision is recommended for younger teenagers.

 

Use Only as Directed

Copyright © 2018 Armstrong Pharmaceuticals, Inc. All rights reserved unless otherwise indicated.

All trademarks are owned by Armstrong Pharmaceuticals, Inc., and its affiliates, or licensed for its use.

Privacy       Terms & Conditions

This site is intended for residents of the United States

 

New to Primatene® MIST

 

 

Primatene® MIST, the epinephrine inhaler propelled by chlorofluorocarbons (CFCs), was phased out in 2011 because the inhaler used CFCs as a propellant to move the medicine out of the inhaler so patients could breathe the medicine into their lungs. The United States signed an international agreement, called the Montreal Protocol on Substances that Deplete the Ozone Layer along with many other countries. In order to comply with obligations made under the Montreal Protocol on Substances that Deplete the Ozone Layer, participating countries agreed to phase-out substances that deplete the ozone layer, including CFCs.

 

 

The new Primatene® MIST is a CFC-free metered dose inhaler (MDI) that uses epinephrine as its active ingredient, the same active ingredient used in the previous Primatene® MIST. The new Primatene® MIST MDI propelled by hydrofluoroalkane (HFA 134a) works differently from the old Primatene® MIST inhaler containing CFCs. Be sure to read the Consumer Information Insert for detailed directions on how to correctly use your new Primatene® MIST metered dose inhaler.

 

 

The new medication container is a pressurized metal canister similar to canisters used in other metered dose inhalers available, instead of the glass container used in the previous Primatene® MIST inhaler propelled by chlorofluorocarbons (CFCs).

 

 

The new Primatene® MIST has a built in spray indicator that shows how many sprays of medication you have left in the container. A full container has 160 sprays. After every 20 sprays, the spray indicator number changes.

 

 

The new Primatene® MIST requires the user to perform the following steps the first time the inhaler is taken out of the box:

 

a. Remove red cap.

 

b. Hold inhaler with opening away from your face and others.

 

c. “Shake then test spray into the air”.

 

You must repeat both actions 4 times to activate your

new inhaler.

 

 

Every time you use your inhaler, before you take an inhalation, you must shake then spray into the air 1 time before each use.

 

Wash your inhaler after each day of use.

 

 

The maximum daily dose of Primatene® MIST is 8 inhalations in 24 hours.

You should see your doctor if you have more than 2 asthma attacks in a week.

 

 

Children under 12 years of age should not use Primatene® MIST.

It is not known if the drug works or is safe in children under age 12.

Adult supervision is recommended for younger teenagers.

 

Use Only as Directed

Copyright © 2018 Armstrong Pharmaceuticals, Inc. All rights reserved unless otherwise indicated.

All trademarks are owned by Armstrong Pharmaceuticals, Inc., and its affiliates, or licensed for its use.

Privacy       Terms & Conditions

This site is intended for residents of the United States

 

 

New to Primatene® MIST

 

 

Primatene® MIST, the epinephrine inhaler propelled by chlorofluorocarbons (CFCs), was phased out in 2011 because the inhaler used CFCs as a propellant to move the medicine out of the inhaler so patients could breathe the medicine into their lungs. The United States signed an international agreement, called the Montreal Protocol on Substances that Deplete the Ozone Layer along with many other countries. In order to comply with obligations made under the Montreal Protocol on Substances that Deplete the Ozone Layer, participating countries agreed to phase-out substances that deplete the ozone layer, including CFCs.

 

 

The new Primatene® MIST is a CFC-free metered dose inhaler (MDI) that uses epinephrine as its active ingredient, the same active ingredient used in the previous Primatene® MIST. The new Primatene® MIST MDI propelled by hydrofluoroalkane (HFA 134a) works differently from the old Primatene® MIST inhaler containing CFCs. Be sure to read the Consumer Information Insert for detailed directions on how to correctly use your new Primatene® MIST metered dose inhaler.

 

 

The new medication container is a pressurized metal canister similar to canisters used in other metered dose inhalers available, instead of the glass container used in the previous Primatene® MIST inhaler propelled by chlorofluorocarbons (CFCs).

 

 

The new Primatene® MIST has a built in spray indicator that shows how many sprays of medication you have left in the container. A full container has 160 sprays. After every 20 sprays, the spray indicator number changes.

 

 

The new Primatene® MIST requires the user to perform the following steps the first time the inhaler is taken out of the box:

 

a. Remove red cap.

 

b. Hold inhaler with opening away from your face and

others.

 

C. “Shake then test spray into the air”.

 

 

You must repeat both actions 4 times to activate

your new inhaler.

Every time you use your inhaler, before you take an inhalation, you must shake then spray into the air 1 time before each use.

 

Wash your inhaler after each day of use.

 

 

The maximum daily dose of Primatene® MIST is 8 inhalations in 24 hours.

You should see your doctor if you have more than 2 asthma attacks in a week.

 

 

Children under 12 years of age should not use Primatene® MIST.

It is not known if the drug works or is safe in children under age 12.

Adult supervision is recommended for younger teenagers.

 

Use Only as Directed

Copyright © 2018 Armstrong Pharmaceuticals, Inc. All rights reserved unless otherwise indicated.

All trademarks are owned by Armstrong Pharmaceuticals, Inc., and its affiliates, or licensed for its use.

Privacy       Terms & Conditions

This site is intended for residents of the United States